• Preliminary tranche of $25 million offers funding in preparation for registrational trial for lead candidate PDS0101
• Convention name scheduled for Thursday, August 25, 2022 at 8:00 AM EDT

FLORHAM PARK, N.J., Aug. 24, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Company (Nasdaq: PDSB), a clinical-stage immunotherapy firm creating a rising pipeline of molecularly focused most cancers immunotherapies and infectious illness vaccines based mostly on the Firm’s proprietary Versamune^® and Infectimune™ T cell activating applied sciences, immediately introduced that it has entered right into a debt financing settlement led by Horizon Expertise Finance Company (NASDAQ: HRZN) (“Horizon”) to supply as much as a $35.zero million time period mortgage.

“We’re happy to accomplice with Horizon, a number one specialty finance firm that has an in depth historical past of supporting modern life science corporations,” stated Frank Bedu-Addo, Chief Govt Officer of PDS Biotech. “We anticipate quite a lot of necessary milestones throughout our oncology and infectious illness applications. This transaction instantly strengthens our stability sheet and offers the monetary assets essential to advance the corporate’s scientific pipeline.  We sit up for our assembly with the U.S. Meals and Drug Administration this quarter to debate the registrational trial design for our lead program.”

As a part of the financing, PDS Biotech obtained an preliminary tranche of $25 million on the shut. The Firm has an choice to obtain an extra $10 million. Every advance of the mortgage will likely be repaid in 48 month-to-month funds consisting of 24 month-to-month funds of curiosity solely, adopted by 24 month-to-month funds of principal and accrued curiosity. In reference to the financing, PDS Biotech issued Horizon warrants to buy as much as 4% of the mortgage quantity, 381,625 of its frequent shares at an train value of $3.6685 per share. Proceeds will likely be used to assist the continued scientific growth of PDS0101 and different product candidates throughout the firm’s pipeline and for basic working capital functions.

Additional info with respect to the debt financing settlement with Horizon will likely be contained in a present report back to be filed on Type 8-Okay by PDS Biotechnology with the Securities and Alternate Fee.

Convention Name and Webcast
The convention name is scheduled for Thursday, August 25, 2022 at 8:00 AM EDT. Contributors ought to dial 877-407-3088 (United States) or 201-389-0927 (Worldwide) and reference convention ID 13732262. To entry the webcast, please use the next hyperlink. The occasion will likely be archived within the investor relations part of PDS Biotech’s web site for six months. 

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy firm creating a rising pipeline of focused most cancers and infectious illness immunotherapies based mostly on our proprietary Versamune^® and Infectimune™ T cell-activating expertise platforms. We imagine our focused Versamune^® based mostly candidates have the potential to beat the constraints of present immunotherapy by inducing massive portions of high-quality, extremely potent polyfunctional tumor particular CD4+ helper and CD8+ killer T cells. Thus far, our lead Versamune^® scientific candidate, PDS0101, has demonstrated the power to scale back tumors and stabilize illness together with authorised and investigational therapeutics in sufferers with a broad vary of HPV16-associated cancers in a number of Part 2 scientific trials. Our Infectimune™ based mostly vaccines have additionally demonstrated the potential to induce not solely strong and sturdy neutralizing antibody responses, but in addition highly effective T cell responses, together with long-lasting reminiscence T cell responses in pre-clinical research up to now. To be taught extra, please go to www.pdsbiotech.com or comply with us on Twitter at @PDSBiotech.

About Horizon Expertise Finance
Horizon Expertise Finance Company (NASDAQ: HRZN) is a number one specialty finance firm that gives capital within the type of secured loans to enterprise capital backed corporations within the expertise, life science, healthcare info and providers, and sustainability industries. The funding goal of Horizon is to maximise its funding portfolio’s return by producing present earnings from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. Horizon is headquartered in Farmington, Connecticut, with a regional workplace in Pleasanton, California, and funding professionals positioned in Portland, Maine, Austin, Texas, and Reston, Virginia. To be taught extra, please go to www.horizontechfinance.com.

Ahead Trying Statements
This communication incorporates forward-looking statements (together with throughout the that means of Part 21E of the US Securities Alternate Act of 1934, as amended, and Part 27A of the US Securities Act of 1933, as amended) regarding PDS Biotechnology Company (the “Firm”) and different issues. These statements might talk about targets, intentions and expectations as to future plans, developments, occasions, outcomes of operations or monetary situation, or in any other case, based mostly on present beliefs of the Firm’s administration, in addition to assumptions made by, and data at the moment accessible to, administration. Ahead-looking statements usually embody statements which are predictive in nature and rely on or check with future occasions or situations, and embody phrases akin to “might,” “will,” “ought to,” “would,” “count on,” “anticipate,” “plan,” “probably,” “imagine,” “estimate,” “venture,” “intend,” “forecast,” “steerage”, “outlook” and different related expressions amongst others. Ahead-looking statements are based mostly on present beliefs and assumptions which are topic to dangers and uncertainties and will not be ensures of future efficiency. Precise outcomes may differ materially from these contained in any forward-looking assertion on account of numerous components, together with, with out limitation: the Firm’s means to guard its mental property rights; the Firm’s anticipated capital necessities, together with the Firm’s anticipated money runway and the Firm’s present expectations concerning its plans for future fairness financings; the Firm’s dependence on further financing to fund its operations and full the event and commercialization of its product candidates, and the dangers that elevating such further capital might limit the Firm’s operations or require the Firm to relinquish rights to the Firm’s applied sciences or product candidates; the Firm’s restricted working historical past within the Firm’s present line of enterprise, which makes it troublesome to judge the Firm’s prospects, the Firm’s marketing strategy or the chance of the Firm’s profitable implementation of such marketing strategy; the timing for the Firm or its companions to provoke the deliberate scientific trials for PDS0101, PDS0203 and different Versamune^® and Infectimune™ based mostly product candidates; the long run success of such trials; the profitable implementation of the Firm’s analysis and growth applications and collaborations, together with any collaboration research regarding PDS0101, PDS0203 and different Versamune^® and Infectimune™ based mostly product candidates and the Firm’s interpretation of the outcomes and findings of such applications and collaborations and whether or not such outcomes are adequate to assist the long run success of the Firm’s product candidates; the success, timing and price of the Firm’s ongoing scientific trials and anticipated scientific trials for the Firm’s present product candidates, together with statements concerning the timing of initiation, tempo of enrollment and completion of the trials (together with the Firm’s means to completely fund its disclosed scientific trials, which assumes no materials modifications to our at the moment projected bills), futility analyses, displays at conferences and information reported in an summary, and receipt of interim or preliminary outcomes (together with, with out limitation, any preclinical outcomes or information), which aren’t essentially indicative of the ultimate outcomes of the Firm’s ongoing scientific trials; any Firm statements about its understanding of product candidates mechanisms of motion and interpretation of preclinical and early scientific outcomes from its scientific growth applications and any collaboration research; and different components, together with legislative, regulatory, political and financial developments not throughout the Firm’s management, together with document inflation, unexpected circumstances or different disruptions to regular enterprise operations arising from or associated to COVID-19 and the continued navy battle between Russia and Ukraine. The foregoing evaluate of necessary components that might trigger precise occasions to vary from expectations shouldn’t be construed as exhaustive and needs to be learn along side statements which are included herein and elsewhere, together with the danger components included within the Firm’s annual and periodic stories filed with the SEC. The forward-looking statements are made solely as of the date of this press launch and, besides as required by relevant regulation, the Firm undertakes no obligation to revise or replace any forward-looking assertion, or to make some other forward-looking statements, whether or not on account of new info, future occasions or in any other case.

Versamune^® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology.

Investor Contacts:
Deanne Randolph
PDS Biotech
Telephone: +1 (908) 517-3613
E-mail: drandolph@pdsbiotech.com

Nicole Jones
CG Capital
Telephone: +1 (404) 736-3838
E-mail: pdsb@cg.capital